Display Settings:

Format

Send to:

Choose Destination
    Trends Cardiovasc Med. 2009 Jul;19(5):158-64.

    Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target?

    Source

    Department of Chemical and Systems Biology, Stanford University School of Medicine, CA 94305-5174, USA.

    Abstract

    Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is emerging as a key enzyme involved in cytoprotection in the heart. ALDH2 mediates both the detoxification of reactive aldehydes such as acetaldehyde and 4-hydroxy-2-nonenal and the bioactivation of nitroglycerin to nitric oxide. In addition, chronic nitrate treatment results in ALDH2 inhibition and contributes to nitrate tolerance. Our laboratory recently identified ALDH2 to be a key mediator of endogenous cytoprotection. We reported that ALDH2 is phosphorylated and activated by the survival kinase protein kinase C epsilon and found a strong inverse correlation between ALDH2 activity and infarct size. We also identified a small molecule ALDH2 activator which reduces myocardial infarct size induced by ischemia/reperfusion in vivo. In this review, we discuss evidence that ALDH2 is a key mediator of endogenous survival signaling in the heart, suggest possible cardioprotective mechanisms mediated by ALDH2 and discuss potential clinical implications of these findings.

    PMID:
    20005475
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2856486
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk